To evaluate the corrective potential of combined JAK2 and ERK1/2 inhibition in human MPN settings, we tested clinical isolates from JAK2V617F MPN patients including PMF, PV and ET. This evidence concerns the gene MAPK3 and myeloproliferative neoplasm.